311 related articles for article (PubMed ID: 22617734)
21. Indirect costs associated with metastatic breast cancer.
Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L
J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016
[TBL] [Abstract][Full Text] [Related]
22. Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030.
Gogate A; Wheeler SB; Reeder-Hayes KE; Ekwueme DU; Fairley TL; Drier S; Trogdon JG
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409255
[TBL] [Abstract][Full Text] [Related]
23. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
24. How to make the best use of limited resources in breast cancer treatment--experiences in Bosnia & Herzegovina.
Obralić N; Beslija S
J BUON; 2006; 11(1):21-9. PubMed ID: 17318948
[TBL] [Abstract][Full Text] [Related]
25. The economic costs of pain in the United States.
Gaskin DJ; Richard P
J Pain; 2012 Aug; 13(8):715-24. PubMed ID: 22607834
[TBL] [Abstract][Full Text] [Related]
26. Economic cost of fecal incontinence.
Xu X; Menees SB; Zochowski MK; Fenner DE
Dis Colon Rectum; 2012 May; 55(5):586-98. PubMed ID: 22513438
[TBL] [Abstract][Full Text] [Related]
27. Costs of illness: United States, 1980.
Parsons PE; Lichtenstein R; Berki SE; Murt HA; Lepkowski JM; Stehouwer SA; Landis JR
Natl Med Care Util Expend Surv C; 1986 Apr; (3):1-90. PubMed ID: 10313412
[TBL] [Abstract][Full Text] [Related]
28. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
29. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
Paramore LC; Thomas SK; Knopf KB; Cragin LS; Fraeman KH
Clin Colorectal Cancer; 2006 May; 6(1):52-8. PubMed ID: 16796792
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
31. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer.
Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Raaijmakers JA; Schellens JH
Breast Cancer Res Treat; 2013 Jun; 139(2):489-95. PubMed ID: 23645005
[TBL] [Abstract][Full Text] [Related]
32. Economic outcomes of breast cancer survivorship: CALGB study 79804.
Hensley ML; Dowell J; Herndon JE; Winer E; Stark N; Weeks JC; Paskett E
Breast Cancer Res Treat; 2005 May; 91(2):153-61. PubMed ID: 15868443
[TBL] [Abstract][Full Text] [Related]
33. Glaucoma in the United States and europe: predicting costs and surgical rates based upon stage of disease.
Lee PP; Kelly SP; Mills RP; Traverso CE; Walt JG; Doyle JJ; Katz LM; Siegartel LR;
J Glaucoma; 2007 Aug; 16(5):471-8. PubMed ID: 17700290
[TBL] [Abstract][Full Text] [Related]
34. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020.
Yabroff KR; Mariotto AB; Feuer E; Brown ML
Health Econ; 2008 Aug; 17(8):947-59. PubMed ID: 17910108
[TBL] [Abstract][Full Text] [Related]
35. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
Sail KR; Franzini L; Lairson DR; Du XL
Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
[TBL] [Abstract][Full Text] [Related]
36. An overview of cancer economics. Based on a presentation by C. Daniel Mullins, PhD.
Am J Manag Care; 1999 Jun; 5(6 Suppl):S371-6. PubMed ID: 10538848
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.
Laas E; Vataire AL; Aballea S; Valentine W; Gligorov J; Chereau E; Rouzier R
J Med Econ; 2012; 15(6):1167-75. PubMed ID: 22853442
[TBL] [Abstract][Full Text] [Related]
38. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract][Full Text] [Related]
39. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
40. Economic burden of cancer across the European Union: a population-based cost analysis.
Luengo-Fernandez R; Leal J; Gray A; Sullivan R
Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
